Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 30821864.
- Also identified by DOI 10.1002/hed.25713.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study aimed on evaluating the expression levels of the immune checkpoint proteins, PD-L1 and PD-L2, in tissue specimens of 175 oral squamous cell carcinomas (OSCC) and 33 corresponding lymph node metastases (LNM). Tissue microarrays of primary OSCC and matched LNM were investigated via immunohistochemistry regarding PD-L1/PD-L2 expression. Results were compared for primary tumors and corresponding metastases and correlated with clinicopathological data. PD-L1 expression in cancer cells correlated significantly with tumor size, and the presence of regional metastases (P < 0.01). PD-L1 expression was significantly higher in metastases as compared to primary OSCC (P < 0.05). Overall survival was significantly worse in patients with higher levels of PD-L1 and PD-L2 score (P < 0.05). This is the first publication to compare PD-L1 and PD-L2 expression in primary OSCC and matched LNM. The results indicate that anti-PD-1 therapy may be of therapeutic use even in early stage OSCC to prevent further progression.
Medical subject headings
- B7-H1 Antigen
- Carcinoma, Squamous Cell
- Head and Neck Neoplasms
- Lymphatic Metastasis
- Programmed Cell Death 1 Ligand 2 Protein